FRLN News and Press, Freeline Therapeutics Holdings plc From 06/24/22

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congr...

Freeline Therapeutics (NASDAQ:FRLN) said on Tuesday it had begun dosing the second cohort in its Phase 1/2 dose confirmation trial of FLT180a in people with hemophilia B. The company said patients in cohort two will receive the same low dose (7.7e11 vg/kg) of FLT180a and optimized p...

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen Cohort one efficacy and safety data to be presented at ISTH Congre...

Wedbush Securities has initiated Sangamo Therapeutics (NASDAQ:SGMO) with a hold rating noting that while it sees promise in isaralgagene civaparvovec for Fabry disease, the candidate needs to demonstrate better durable efficacy and safety compared to current treatments. The firm has a $5 pric...

U.K.-based clinical-stage biotech Freeline Therapeutics (NASDAQ:FRLN) dropped ~6% in the post-market Friday after the company said that it is not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq. Informing about its non-complia...

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggreg...

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from the Nasdaq Stock Market LLC (“Nasdaq”...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Freeline Therapeutics press release (NASDAQ:FRLN): Q1 GAAP EPS of -$0.63. Cash and cash equivalents were $113.1 million as of March 31, 2022, as compared to $117.7 million as of year-end 2021. For further details see: Freeline Therapeutics GAAP EPS of -$0.63

Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership team LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holding...